Kidney cancer: news in 2008;Cancer du rein : actualités 2008

Progres en Urologie

Volumn 18, Issue SUPPL. 6, 2008, Pages

  Patard, J J ^a   Lechevallier, E ^b   Descazeaud, A ^c  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^b Child and Adolescent Psychopathology Unit Salvator Hospital Public Assistance Marseille Hospitals University Aix Marseille II   (France)

^c DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

Antiangiogenics; Biopsies, Nephrectomy; Conservative surgery; Kidney cancer; Laparoscopy

Indexed keywords

ARTICLE; HUMAN; KIDNEY TUMOR; ORGANIZATION;

CONGRESSES AS TOPIC; HUMANS; KIDNEY NEOPLASMS;

EID: 52149108491     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1166-7087(08)73939-3     Document Type: Article

References (35)

1. Ljungberg B., Hanbury D.C., Kuczyk M.A., Merseburger A.S., Mulders P.F.A., Patard J.J., et al. Renal cell carcinoma guideline. Eur Urol 51 (2007) 1502-1510
2. Trabulsi E.J., Kalra P., and Gomella L.G. New approaches to the minimally invasive treatment of kidney tumors. Cancer J 11 (2005) 57-63
3. American Cancer Society. Available at URL: http://www.cancer.org. Accessed September 2007.
4. Schmidbauer J., Remzi M., Memarsadeghi M., Klinger H.C., Wiener H., Hainz-Peer G., et al. Diagnostic accuracy of percutaneous biopsy of renal masses guided by computerized tomography. Eur Urol Suppl 6 (2007) 132 (abstract no. 440)
5. Mattar K., Azuero J., Rendon R., Morash C., Siemens D.R., Chin J.L., et al. The natural history of small renal masses: a prospective multi-center Canadian trial. J Urol 177 Suppl (2007) 169-170 (abstract no. 509)
6. Nguyen M.M., Stein R.J., Hafron J.M., Aron M., Columbo J.R., Gianduzzo T.R., et al. The metastatic potential of small renal cancers is higher than previously believed. J Urol 177 Suppl (2007) 167 (abstract no. 501)
7. Crispen P.L., Dougherty J., Greenberg R.E., Chen D., and Uzzo R.G. High nuclear grade is associated with increased growth kinetics during active surveillance of clear cell renal carcinoma. J Urol 177 Suppl (2007) 215-216 (abstract no. 642)
8. Trinh Q.D., Karakiewicz P., Jeldres C., Salomon L., De La Taille A., Tostain J., et al. Age is a major determinant of renal cell carcinoma-specific mortality after nephrectomy. Eur Urol Suppl 6 (2007) 63 (abstract no. 163)
9. Crepel M., Verhoest G., Bernhard J.C., Ferrière J.M., Bellec L., Soulié M., et al. Impact of histology on cancer control after nephron sparing surgery for renal cell carcinoma. Eur Urol Suppl 6 (2007) 133 (abstract no. 443)
10. Zini L., Leroy X., Garnier-Destrieux L., Fantoni J.C., Lemaitre L., Biserte J., et al. Inferior vena cava (IVC) wall invasion by a tumour thrombus in renal cell carcinoma: prediction of invasion and correlation with disease progression. J Urol 177 Suppl (2007) 300 (abstract no. 904)
11. Klatte T., Wunderlich H., Patard J.-J., Kleid M.D., Lam J.S., Junker K., et al. Prognosis and survival of synchronous bilateral renal cell carcinoma: a multicenter experience. J Urol 177 Suppl (2007) 303-304 (abstract no. 915)
12. Lane B.R., Babineau D., Gill I.S., and Novick A.C. Factors predicting renal functional outcome after partial nephrectomy. J Urol 177 Suppl (2007) 211-212 (abstract no. 631)
13. Gill I.S., Kavoussi L.R., Lane B.R., Blute M.L., Babineau D., Colombo J.R., et al. Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol 178 (2007) 41-46
14. Lane B.R., and Gill I.S. Five year outcomes of laparoscopic partial nephrectomy. J Urol 177 Suppl (2007) 165-166 (abstract no. 496)
15. Lane B.R., and Novick A.C. Comparison of laparoscopic and open partial nephrectomy for a single renal tumour in a solitary kidney. J Urol 177 Suppl (2007) 217-218 (abstract no. 648)
16. Beri A., Lattouf J.B., Gruüll M., Leeb K., Jeschke S., and Janetschek G. Laparoscopic partial nephrectomy using renal artery perfusion for cold ischemia. J Urol 177 Suppl (2007) 407-408 (abstract no. 1237)
17. Pertia A., and Managadze L. Long-term results of simple enucleation for the treatment of small renal carcinoma. Eur Urol Suppl 6 (2007) 65 (abstract no. 170)
18. Johnson A., Bratslavsky G., Sudarshan S., Liu J., Linehan W.M., and Pinto P.A. Feasibility and outcomes of repeat partial nephrectomy on the same kidney: NCI experience. J Urol 177 Suppl (2007) 427 (abstract no. 1298)
19. Schwentner C., Lunacek A., Pelzer A.E., Steiner H., Neururer R., Bartsch G., et al. Single center experience and extended follow-up of robotic partial nephrectomy. J Urol 177 Suppl (2007) 409 (abstract no. 1241)
20. Vander Eeckt K., Joniau S., and Van Poppel H. Outcome of nephron sparing surgery for T1b renal cell carcinoma. Eur Urol Suppl 6 (2007) 265 (abstract no. 972)
21. Trinh Q.-D., Karakiewicz P.I., Bhojani N., Fournier-Cloutier V., Hutterer G.C., Crepel M., et al. Nephronsparing surgery does not undermine renal cell carcinoma- specific survival in patients with pT3 renal cell carcinoma. J Urol 177 Suppl (2007) 411 (abstract no. 1246)
22. Huang W.C., Elkin E.B., Jang T.L., and Russo P. Radical nephrectomy is associated with increased mortality in patients with small renal tumors. J Urol 177 Suppl (2007) 164-165 (abstract no. 493)
23. Thompson R.H., Boorjian S.A., Lohse C.M., Leibovich B.C., and Blute M.L. Is partial nephrectomy for small renal masses associated with improved overall survival compared with radical nephrectomy?. J Urol 177 Suppl (2007) 215 (abstract no. 641)
24. Nomiya T., Tsuji H., Hirasawa N., Kato H., Kamada T., Mizoe J., et al. Carbon Ion Radiotherapy for Renal Cell Carcinoma: Outcome of a Pilot Study. Int J Radiat Oncol Biol Phys 69 (2007) S324 (Abstract no 2219)
25. Thomas A., Lane B.R., Rini B.I., and Campbell S.C. Effect of sunitinib in patients with unresectable primary renal cell carcinoma. J Urol 177 Suppl (2007) 167-168 (abstract no. 502)
26. Bukowski R.M., Eisen T., Szczylik C., Stadler W.M., Simantov R., Shan M., et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma; survival and biomarker analysis. J Clin Oncol 25 Suppl (2007) 240s (abstract no. 5023)
27. Motzer R.J., Figlin R.A., Hutson T.E., Tomczak P., Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors. J Clin Oncol 25 Suppl (2007) 241s (abstract no. 5024)
28. Golshayan A., Choueiri T.K., Elson P., Garcia J.A., Khaswneh M., Usman S., et al. Clinical factors associated with outcome in metastatic renal cell carcinoma patients treated with VEGF-targeted therapy. J Clin Oncol 25 Suppl (2007) 246s (abstract no. 5046)
29. Choueiri T.K., Vaziri S.A., Rini B.I., Elson P., Bhalla I., Jaeger E., et al. Use of Von-Hippel Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF) - targeted therapy in metastatic renal cell carcinoma (RCC). J Clin Oncol 25 Suppl (2007) 238s (abstract no. 5012)
30. Szczylik C., Demkow T., Staehler M., Rolland F., Negrier S., Hutson T.E., et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma:Final results. J Clin Oncol 25 Suppl (2007) 241s (abstract no. 5025)
31. Patard J.-J., Rioux-Leclercq N., and Fergelot P. Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol. 49 (2006) 633-643
32. Escudier B., Koralewski P., Pluzanska A., Ravaud A., Bracarda S., Szcylik C., et al. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs. placebo/interferon-α2a as first-line therapy in metastatic renal cell carcinoma. J Clin Oncol 25 Suppl (2007) 2s (abstract no. 3)
33. Plantade A., Choueiri T., Escudier B., Rini B., Negrier S., Ravaud A., et al. Treatment outcome for metastatic papillary and chromophobe renal cell carcinoma (RCC) patients treated with tyrosine-kinase inhibitors (TKIs) sunitinib and sorafenib. J Clin Oncol 25 Suppl (2007) 244s (abstract no. 5037)
34. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Phaze III randomized trial of sunitnib malate (SU1 1248) versus interferon- alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 24 Suppl (2006) 2 (abstract no. LBA3)
35. Dutcher J.P., Szczylik C., Tannir N., Benedetto P., Ruff P., Hsu A., et al. Correlation of survival with tumor histology, age and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). J Clin Oncol 25 Suppl (2007) 243s (abstract no. 5033)